combretastatin
Small moleculeexperimental
Combretastatin is a dihydrostilbenoid found in Combretum afrum. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00507429)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cadherin-5INHIBITOR
inhibitor - CDH5
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C[C@@H](O)c2cc(OC)c(OC)c(OC)c2)cc1O- Mol. weight
- 334.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCombretastatin ↗
- ChEMBLCHEMBL246600 ↗
Also known as
- 3-hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)benzeneethanol
- combretastatin
- combretastatin
- combretastatin
- combretastatin
- nsc 348103
- nsc-348103
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00507429 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2007 | Mateon Therapeutics, Yale University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mateon Therapeutics | For profit | 1 | 1 | 1 | 2007 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1